Medscape
SAN DIEGO — Patients with diffuse large B-cell lymphoma (DLBCL) continue to show superior progression-free survival at 5 years with first-line pola-R-CHP compared with the R-CHOP regimen, according to updated results of the phase 3 POLARIX study. These findings “confirm pola-R-CHP as the standard of care for patients with previously untreated intermediate- or high-risk DLBCL,” …
Read More
POLARIX: Extended Results Confirm Standard of Care for DLBCL
Sharie Catt
08:21
SAN DIEGO — Patients with diffuse large B-cell lymphoma (DLBCL) continue to show superior progression-free survival at 5 years with first-line pola-R-CHP compared with the R-CHOP regimen, according to updated results of the phase 3 POLARIX study. These findings “confirm pola-R-CHP as the standard of care for patients with previously untreated intermediate- or high-risk DLBCL,”
